Harriet completed her MSci in Chemistry at Imperial College London, before undertaking an MSc in Drug Discovery at Newcastle University. In 2018, she joined the Waring group at Newcastle to undertake her PhD which focused on the development of DNA-compatible chemistry for application in DNA-encoded libraries (DELs).
Harriet joined the Kawamura group as an EPSRC Doctoral Prize Fellow in 2022, where she employed DELs to begin investigation into alternative modalities for drug discovery, CyPeMs (cyclic peptide-small molecule hybrids). Since October 2024, Harriet has been a Royal Commission for the Exhibition of 1851 Research Fellow working between the Chemical Biology and Medicinal Chemistry groups. Her current research focuses on the application of CyPeMs within neurodegenerative disease (NDD) and antimicrobial resistance (AMR) alongside technology advancement for DELs.